share_log

Chardan Capital Initiates Coverage On Xilio Therapeutics With Buy Rating, Announces Price Target of $7

Chardan Capital Initiates Coverage On Xilio Therapeutics With Buy Rating, Announces Price Target of $7

Chardan Capital以买入评级开始对Xilio Therapeutics进行报道,宣布目标股价为7美元
Benzinga Real-time News ·  2022/12/21 06:22

Chardan Capital analyst Matthew Barcus initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Buy rating and announces Price Target of $7.

Chardan Capital分析师马修·巴库斯以买入评级启动对西利奥治疗公司(纳斯达克:XLO)的报道,并宣布目标价为7美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发